Assessing cognition and function in Alzheimer's disease clinical trials: Do we have the right tools?

Alzheimer's and Dementia

Volumn 10, Issue 6, 2014, Pages 853-860

  Snyder, Peter J ^a   Kahle Wrobleski, Kristin ^b   Brannan, Stephen ^c   Miller, David S ^d   Schindler, Rachel J ^e   Desanti, Susan ^f   Ryan, J Michael ^g   Morrison, Glenn ^h   Grundman, Michael ⁱ   Chandler, Julie ^j   Caselli, Richard J ^k   Isaac, Maria ^l   Bain, Lisa ^m   Carrillo, Maria C ⁿ  

^a BROWN UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c TAKEDA DEVELOPMENT CENTER AMERICAS   (United States)

^d Bracket   (United States)

^e PFIZER INC   (United States)

^f Piramal Enterprises Limited   (India)

^g NOVARTIS PHARMA AG   (Switzerland)

^h Lumos Labs Inc   (United States)

ⁱ Global R and D Partners LLC   (United States)

^j MERCK RESEARCH LABORATORIES   (United States)

^k MAYO CLINIC   (United States)

^l EUROPEAN MEDICINES AGENCY   (United Kingdom)

^m Independent Science Writer   (United States)

ⁿ ALZHEIMER'S ASSOCIATION   (United States)

more..

Author keywords

Alzheimer's disease; Biomarkers; Diagnostic criteria

Indexed keywords

ALZHEIMER DISEASE; ASSESSMENT OF HUMANS; CLINICAL TRIAL (TOPIC); COGNITIVE RESERVE; DAILY LIFE ACTIVITY; EPISODIC MEMORY; EVERYDAY COGNITION SCALE; EXECUTIVE FUNCTION; FUNCTIONAL ACTIVITIES QUESTIONNAIRE; FUNCTIONAL ASSESSMENT; HUMAN; LAWTON INSTRUMENTAL ACTIVITIES OF DAILY LIVING SCALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; REVIEW; REY AUDITORY VERBAL LEARNING TEST; COGNITION DISORDERS; COMPLICATION; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; HUMANS; NEUROPSYCHOLOGICAL TESTS;

EID: 84927161835     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2014.07.158     Document Type: Article

References (49)

1. U.S. Department of Health and Human Services. National Plan to Address Alzheimer's Disease: 2013 Update, Available at http://aspe.hhs.gov/daltcp/napa/natlplan.shtml. Accessed November 27, 2013.
2. Food and Drug Administration. Draft Guidance for Industry. Alzheimer's disease: developing drugs for the treatment of early stage disease. Availalbe at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf. Accessed February 24, 2013.
3. M. Albert, D. Blacker, M.B. Moss, R. Tanzi, and J.J. McArdle Longitudinal change in cognitive performance among individuals with mild cognitive impairment Neuropsychology 21 2007 158 169
4. N. Kozauer, and R. Katz Regulatory innovation and drug development for early-stage Alzheimer's disease N Engl J Med 368 2013 1169 1171
5. U.S. National Archives and Records Administration. Code of federal regulations. Title 21, Subpart H 314.510. 2012.
6. Centers for Medicare and Medicaid Services. Decision memo for beta-amyloid positron emission tomography in dementia and neurodegenerative disease (CAG-00431N). 2013.
7. N.L. Foster, K. Mottola, and J.M. Hoffman Coverage with evidence development: what to consider JAMA Neurol 71(4) 2014 399 400
8. A. Relyea-Chew Ethical considerations in CMS's coverage with evidence development J Am Coll Radiol 8 2011 838 841
9. A.M. Tucker, and Y. Stern Cognitive reserve in aging Curr Alzheimer Res 8 2011 354 360
10. Y.Y. Lim, P. Maruff, R.H. Pietrzak, D. Ames, K.A. Ellis, and K. Harrington Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease Brain 137 Pt 1 2014 221 231
11. E. Tulving Episodic and semantic memory E. Tulving, W. Donaldson, Organization of Memory 1972 Academic Press New York 381 403
12. Jedynak BM, Lang A, Liu B, Katz E, Zhang Y, Wyman BT, et al. Longitudinal normalization of multiple biomarkers predicts the timing of biomarker changes in Alzheimer's disease progression. Proc Natl Acad Sci U S A. in press.
13. J.J. Gomar, M.T. Bobes-Bascaran, C. Conejero-Goldberg, P. Davies, and T.E. Goldberg Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative Arch Gen Psychiatry 68 2011 961 969
14. R.J. Caselli, D.E. Locke, A.C. Dueck, D.S. Knopman, B.K. Woodruff, and C. Hoffman-Snyder The neuropsychology of normal aging and preclinical Alzheimer's disease Alzheimers Dement 10 2014 84 92
15. E.M. Reiman, K. Chen, X. Liu, D. Bandy, M. Yu, and W. Lee Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease Proc Natl Acad Sci U S A 106 2009 6820 6825
16. Y.Y. Lim, P. Maruff, R.H. Pietrzak, D. Ames, K.A. Ellis, and K. Harrington Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease Brain 137 2014 221 231
17. M. Sano, S. Egelko, M. Donohue, S. Paparello, S. Ferris, and J. Kaye Satisfaction of elderly volunteers with home-based clinical trial participation Alzheimer Dement 9 4, Supplement 2013 P781
18. L. Frank, W.R. Lenderking, K. Howard, and M. Cantillon Patient self-report for evaluating mild cognitive impairment and prodromal Alzheimer's disease Alzheimers Res Ther 3 2011 35
19. K.A. Gifford, D. Liu, Z. Lu, Y. Tripodis, N.G. Cantwell, and J. Palmisano The source of cognitive complaints predicts diagnostic conversion differentially among nondemented older adults Alzheimers Dement 10 2014 319 327
20. R.J. Caselli, K. Chen, D.E. Locke, W. Lee, A. Roontiva, and D. Bandy Subjective cognitive decline: self and informant comparisons Alzheimers Dement 10 2014 93 98
21. N. Ayutyanont, J.B. Langbaum, S.B. Hendrix, K. Chen, A.S. Fleisher, and M. Friesenhahn The Alzheimer's Prevention Initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers J Clin Psychiatry 75 (6) 2014 652 660
22. J.B. Langbaum, S.B. Hendrix, N. Ayutyanont, K. Chen, A.S. Fleisher, and R.C. Shah An empirically derived composite cognitive endpoint with improved power to track and evaluate treatmetns for preclinical Alzheimer's disease Alzheimer Dement 10 2014 666 674
23. A.D. Roses, A.M. Saunders, M.W. Lutz, N. Zhang, A.R. Hariri, and K.E. Asin New applications of disease genetics and pharmacogenetics to drug development Curr Opin Pharmacol 14C 2014 81 89
24. S. Hendrix, V. Logovinsky, C. Perdomo, J. Wang, and A. Satlin A new tool for optimizing responsiveness to decline in early AD - abstract OC12 J of Nutr Health Aging 16 2012 805
25. N. Raghavan, M.N. Samtani, M. Farnum, E. Yang, G. Novak, and M. Grundman The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials Alzheimers Dement 9 1 Suppl 2013 S21 31
26. T.E. Goldberg, J. Koppel, L. Keehlisen, E. Christen, U. Dreses-Werringloer, and C. Conejero-Goldberg Performance-based measures of everyday function in mild cognitive impairment Am J Psychiatry 167 2010 845 853
27. J.J. Gomar, P.D. Harvey, M.T. Bobes-Bascaran, P. Davies, and T.E. Goldberg Development and cross-validation of the UPSA short form for the performance-based functional assessment of patients with mild cognitive impairment and Alzheimer disease Am J Geriatr Psychiatry 19 2011 915 922
28. B. Reisberg, S.H. Ferris, M.J. de Leon, and T. Crook The Global Deterioration Scale for assessment of primary degenerative dementia Am J Psychiatry 139 1982 1136 1139
29. S. Gauthier, B. Reisberg, M. Zaudig, R.C. Petersen, K. Ritchie, and K. Broich Mild cognitive impairment Lancet 367 2006 1262 1270
30. A. Perrotin, E.C. Mormino, C.M. Madison, A.O. Hayenga, and W.J. Jagust Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals Arch Neurol 69 2012 223 229
31. K. Rockwood, M. Richard, C. Leibman, L. Mucha, and A. Mitnitski Staging dementia from symptom profiles on a care partner website J Med Internet Res 15 2013 e145
32. Y.T. Quiroz, B.A. Ally, K. Celone, J. McKeever, A.L. Ruiz-Rizzo, and F. Lopera Event-related potential markers of brain changes in preclinical familial Alzheimer disease Neurology 77 2011 469 475
33. J.D. Ragland, C. Ranganath, D.M. Barch, J.M. Gold, B. Haley, and A.W. MacDonald 3rd Relational and Item-Specific Encoding (RISE): task development and psychometric characteristics Schizophr Bull 38 2011 114 124
34. J.J. Gomar, M.L. Gordon, D. Dickinson, P.B. Kingsley, A.M. Ulug, and L. Keehlisen APOE genotype modulates proton magnetic resonance spectroscopy metabolites in the aging brain Biol Psychiatry 75(9) 2013 686 692
35. G.A. Marshall, R.E. Amariglio, R.A. Sperling, and D.M. Rentz Activities of daily living: where do they fit in the diagnosis of Alzheimer's disease? Neurodegener Dis Manag 2 2012 483 491
36. Y.L. Chang, M.W. Bondi, L.K. McEvoy, C. Fennema-Notestine, D.P. Salmon, and D. Galasko Global clinical dementia rating of 0.5 in MCI masks variability related to level of function Neurology 76 2011 652 659
37. M.P. Lawton, and E.M. Brody Assessment of older people: self-maintaining and instrumental activities of daily living Gerontologist 9 1969 179 186
38. R.I. Pfeffer, T.T. Kurosaki, C.H. Harrah Jr., J.M. Chance, and S. Filos Measurement of functional activities in older adults in the community J Gerontol 37 1982 323 329
39. D. Galasko, D. Bennett, M. Sano, C. Ernesto, R. Thomas, and M. Grundman An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study Alzheimer Dis Assoc Disord 11 Suppl 2 1997 S33 S39
40. D. Galasko, D.A. Bennett, M. Sano, D. Marson, J. Kaye, and S.D. Edland ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials Alzheimer Dis Assoc Disord 20 4 Suppl 3 2006 S152 S169
41. S.T. Farias, D. Mungas, B.R. Reed, D. Cahn-Weiner, W. Jagust, and K. Baynes The measurement of everyday cognition (ECog): scale development and psychometric properties Neuropsychology 22 2008 531 544
42. R. Schulz, T.B. Cook, S.R. Beach, J.H. Lingler, L.M. Martire, and J.K. Monin Magnitude and causes of bias among family caregivers rating Alzheimer disease patients Am J Geriatr Psychiatry 21 2013 14 25
43. K.L. Triebel, R. Martin, H.R. Griffith, J. Marceaux, O.C. Okonkwo, and L. Harrell Declining financial capacity in mild cognitive impairment: a 1-year longitudinal study Neurology 73 2009 928 934
44. V.G. Wadley, O. Okonkwo, M. Crowe, and L.A. Ross-Meadows Mild cognitive impairment and everyday function: evidence of reduced speed in performing instrumental activities of daily living Am J Geriatr Psychiatry 16 2008 416 424
45. V.G. Wadley, O. Okonkwo, M. Crowe, D.E. Vance, J.M. Elgin, and K.K. Ball Mild cognitive impairment and everyday function: an investigation of driving performance J Geriatr Psychiatry Neurol 22 2009 87 94
46. O.C. Okonkwo, V.G. Wadley, K. Ball, D.E. Vance, and M. Crowe Dissociations in visual attention deficits among persons with mild cognitive impairment Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 15 2008 492 505
47. O.C. Okonkwo, H.R. Griffith, D.E. Vance, D.C. Marson, K.K. Ball, and V.G. Wadley Awareness of functional difficulties in mild cognitive impairment: a multidomain assessment approach J Am Geriatr Soc 57 2009 978 984
48. M. Isaac, S. Vamvakas, E. Abadie, B. Jonsson, C. Gispen, and L. Pani Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden-regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials Eur Neuropsychopharmacol 21 2011 781 788
49. European Medicines Agency. Concept paper on need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease and other dementias. EMA/CHMP/617734. 2013.